Back to top

Aurinia Unchanged on Unveiling Lupus Treatment

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) began Monday trading flat, after it announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Aurinia Pharmaceuticals Inc (AUPH)